- Home
- CREV vs THAR Comparison
CREV vs THAR Comparison
Compare CREV & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- THAR
- Stock Information
- Founded
- CREV 2007
- THAR 2017
- Country
- CREV Ireland
- THAR United States
- Employees
- CREV N/A
- THAR N/A
- Industry
- CREV
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- THAR Health Care
- Exchange
- CREV Nasdaq
- THAR Nasdaq
- Market Cap
- CREV 6.0M
- THAR 5.5M
- IPO Year
- CREV N/A
- THAR 2022
- Fundamental
- Price
- CREV $4.55
- THAR $1.75
- Analyst Decision
- CREV
- THAR Strong Buy
- Analyst Count
- CREV 0
- THAR 1
- Target Price
- CREV N/A
- THAR $17.00
- AVG Volume (30 Days)
- CREV 667.2K
- THAR 42.9K
- Earning Date
- CREV 05-14-2025
- THAR 08-08-2025
- Dividend Yield
- CREV N/A
- THAR N/A
- EPS Growth
- CREV N/A
- THAR N/A
- EPS
- CREV N/A
- THAR N/A
- Revenue
- CREV $39,261,077.00
- THAR N/A
- Revenue This Year
- CREV $40.76
- THAR N/A
- Revenue Next Year
- CREV $86.18
- THAR N/A
- P/E Ratio
- CREV N/A
- THAR N/A
- Revenue Growth
- CREV 41.52
- THAR N/A
- 52 Week Low
- CREV $2.00
- THAR $0.95
- 52 Week High
- CREV $14.19
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- CREV 60.60
- THAR 57.04
- Support Level
- CREV $2.51
- THAR $1.60
- Resistance Level
- CREV $4.26
- THAR $1.87
- Average True Range (ATR)
- CREV 0.57
- THAR 0.14
- MACD
- CREV 0.14
- THAR 0.01
- Stochastic Oscillator
- CREV 71.29
- THAR 69.70
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.